DipeshUpretyMD

Oncology • Detroit, MI

Thoracic Cancer

Assistant Professor

Join to view full profile

Dr. Uprety is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Uprety's full profile

Already have an account?

Office
4100 John R St
Detroit, MI 48201
Phone+1 313-576-8722

Summary

Dr. Uprety is an Assistant Professor in the Department of Medical Oncology at the Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, specializing in the care of patients with lung cancer. Dr. Uprety is actively involved in clinical research, focusing primarily on biomarker-driven cancer treatments, investigating resistance mechanisms to immunotherapy, and assessing treatment regimens for non-small cell lung cancer patients experiencing disease progression on immunotherapy. Additionally, he is actively involved in studying population access to care, treatment utilization, treatment outcomes and racial disparities.

Education & Training

Gundersen Lutheran Medical FoundationFellowship, Hematology and Medical Oncology, 2019
Abington Memorial HospitalResidency, Internal Medicine, 2013 - 2016
B.P. Koirala Institute of Health SciencesClass of 2009

Certifications & Licensure

MI State Medical License 2020 - 2026
MN State Medical License 2019 - 2020
WI State Medical License 2016 - 2019
PA State Medical License 2013 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C Start of enrollment: 2023 Dec 21
Recruiting
Phase 3
A Study of DF6002 Alone and in Combination With Nivolumab Start of enrollment: 2020 Jul 13
Recruiting
Phase 1, Phase 2
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Start of enrollment: 2017 Mar 07
Recruiting
Phase 1, Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Start of enrollment: 2020 Oct 29
Recruiting
Phase 1, Phase 2
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain Start of enrollment: 2022 Apr 19
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Racial and socioeconomic disparities in survival among patients with metastatic non-small cell lung cancer.
Dipesh Uprety, Randell Seaton, Tarik Hadid, Hirva Mamdani, Ammar Sukari
Journal of the National Cancer Institute. 2024-10-01
Selective loss of Y chromosomes in lung adenocarcinoma modulates the tumor immune environment through cancer/testis antigens.
Jonas Fischer, Katherine H Shutta, Chen Chen, Viola Fanfani, Enakshi Saha
Biorxiv. 2024-09-22
2 citations
Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemio...
Yating Wang, Kyle Kondrat, Janak Adhikari, Quynh Nguyen, Qian Yu
Cancer. 2024-07-10

Press Mentions

Deaths from Advanced Lung Cancer Have Dropped Significantly Since Immunotherapy Became Standard-of-CareAugust 12th, 2024
Advanced Lung Cancer Deaths Drop with ImmunotherapyAugust 7th, 2024
The Largest Population-Based Study to Date Supports the Survival Benefits of Immunotherapy for People with Metastatic Non-Small Cell Lung CancerJuly 29th, 2024